Captrust Financial Advisors acquired a new stake in Medtronic plc. (NYSE:MDT) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 5,697 shares of the medical technology company’s stock, valued at approximately $463,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of MDT. Janus Henderson Group PLC acquired a new position in Medtronic in the 3rd quarter valued at $579,952,000. BlackRock Inc. grew its holdings in Medtronic by 6.4% in the 4th quarter. BlackRock Inc. now owns 94,595,580 shares of the medical technology company’s stock valued at $7,638,592,000 after buying an additional 5,688,180 shares in the last quarter. American Century Companies Inc. grew its holdings in Medtronic by 35.0% in the 3rd quarter. American Century Companies Inc. now owns 9,082,452 shares of the medical technology company’s stock valued at $706,342,000 after buying an additional 2,354,467 shares in the last quarter. Asset Management One Co. Ltd. grew its holdings in Medtronic by 3,863.2% in the 3rd quarter. Asset Management One Co. Ltd. now owns 2,064,912 shares of the medical technology company’s stock valued at $160,588,000 after buying an additional 2,012,810 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in Medtronic by 20.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 11,388,438 shares of the medical technology company’s stock valued at $885,673,000 after buying an additional 1,954,535 shares in the last quarter. 80.79% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Medtronic plc. (MDT) opened at $82.30 on Thursday. The company has a current ratio of 2.43, a quick ratio of 2.09 and a debt-to-equity ratio of 0.51. Medtronic plc. has a 1 year low of $76.51 and a 1 year high of $89.72. The firm has a market capitalization of $113,130.00, a price-to-earnings ratio of 40.34, a P/E/G ratio of 2.36 and a beta of 0.97.
Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 20th. The medical technology company reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.01. Medtronic had a return on equity of 12.65% and a net margin of 9.44%. The business had revenue of $7.37 billion during the quarter, compared to the consensus estimate of $7.20 billion. During the same period in the prior year, the company earned $1.12 EPS. Medtronic’s revenue for the quarter was up 1.2% on a year-over-year basis. analysts predict that Medtronic plc. will post 4.75 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 23rd will be given a dividend of $0.46 per share. The ex-dividend date of this dividend is Thursday, March 22nd. This represents a $1.84 annualized dividend and a dividend yield of 2.24%. Medtronic’s dividend payout ratio is currently 90.20%.
MDT has been the topic of a number of research reports. SunTrust Banks set a $92.00 price objective on Medtronic and gave the company a “buy” rating in a report on Sunday, November 19th. Evercore ISI assumed coverage on Medtronic in a report on Wednesday, January 3rd. They set an “outperform” rating and a $92.50 target price on the stock. Citigroup reissued a “buy” rating and set a $93.00 target price (down from $100.00) on shares of Medtronic in a report on Thursday, February 22nd. Oppenheimer reissued a “buy” rating on shares of Medtronic in a report on Thursday, December 21st. Finally, BMO Capital Markets increased their target price on Medtronic to $94.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $91.50.
In related news, EVP Bryan C. Hanson sold 16,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $82.82, for a total transaction of $1,325,120.00. Following the completion of the sale, the executive vice president now directly owns 88,818 shares in the company, valued at approximately $7,355,906.76. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director James T. Lenehan sold 1,306 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $83.56, for a total value of $109,129.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 146,469 shares of company stock valued at $12,341,174. 0.31% of the stock is owned by corporate insiders.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.